Printer Friendly

PanGeo Announces Year-End Financial Results.

Business Editors


PanGeo (TSE:PIL)
-- Consolidated revenues for the year rise 89% to 60.0 million

-- Income climbs to $8.3 million, before interest, income taxes, depreciation
and amortization.

-- Net income for the year grew to $7.9 million ($5.0 million before tax
benefit of loss carried forward of $2.9 million)

-- Q4 consolidated revenues rise 55% to $19.4 million and income climbs 136% to
$2.6 million, before interest, income taxes, depreciation and amortization.

PanGeo Pharma Inc. (PIL-TSE) reported today consolidated revenues of $60.0 million for the year ended January 31, 2002, an increase of 89% over revenues of $31.7 million the previous year. Operating income (EBITDA) before interest, income taxes, depreciation and amortization for the year increased by 196% to $8.3 million, compared with $2.8 million on the same basis for the preceding year. Operating margin increased to 13.8% compared to 8.7% last year. Fully diluted earnings per share rose to $.13 up from $.01 the preceding year. Net Income rose to $7.9 million ($5.0 million before tax benefit of loss carried forward of $2.9 million) versus $486 thousand the previous year.

Fiscal 2002 was a year in which PanGeo made solid progress in its continuing evolution from private label manufacturer to a leading specialty pharmaceutical company. Producing solid gains in its second profitable year, PanGeo has set the stage for continued performance over the longer term.

Fourth Quarter

Revenues for the fourth quarter increased to $19.4 million up from $12.4 million in the previous year representing an increase of 56.5%. Operating income (EBITDA) was $2.6 million compared with last year of $1.1 million. Operating margin increased to 13.5% from 9.2%. Net income was $4.2 million (after the income tax benefit of loss carry forwards of $2.9 million) or $0.07 per share compared with $317 thousand or $0.01 per share in the corresponding period last year.

The complete year-end financial statements along with Management's Discussion and Analysis can be viewed on our website at or by requesting a copy through our investor relations department at

PanGeo Pharma will host a conference call at 8:30am on Tuesday May 7 to discuss in detail the results. To access the call please dial 416/695-5806 or toll free: 800/273-9672. The conference call will also be webcast and can be accessed at

PanGeo Pharma Inc. is a specialty pharmaceutical company with core competencies in pharmaceutical manufacturing. The company manufactures and supplies a range of specialty pharmaceutical products and services to international markets. The Company employs over 500 people working in eight affiliate companies internationally.
COPYRIGHT 2002 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2002, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:May 6, 2002
Previous Article:Investment Grade Municipal Income Fund Inc. - Dividend Declaration and Portfolio Statistics.
Next Article:Garrett Willis Wins Pro Division of The Vinny.

Related Articles
The audit from the inside.
When to deduct annual expenditures.
Deductions for bonus plans: attempting to ensure an accelerated deduction.
Midtown business growth leads office market recovery.
Section 404 compliance in the annual report: assessing control deficiencies now is a documented process required of management.
The Securities and Exchange Commission amended its rules to allow certain larger companies an additional year to comply with internal control...
Tenants take it to the max in search for high-end space.
1Q office vacancies nudge higher on Long Island.
Industrial vacancies down, rents up on Long Island.
Long Island 1Q vacancies nudge higher as rents edge up.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters